In this issue of JAMA Internal Medicine is an analysis by Heyward et al1 about the oversight the US Food and Drug Administration (FDA) has attempted to impose on prescription opioids. The authors note that there is insufficient evidence to conclude that the FDA’s efforts to mitigate risk from opioids has been successful. The article does point toward the conclusion that the FDA has tools that could mitigate opioid risks more effectively if the agency would be more assertive in using its power to control opioid prescribing, manufacturing, and distribution.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Hubbard WK. Getting Serious About Opioid Regulation. JAMA Intern Med. 2020;180(2):309–310. doi:10.1001/jamainternmed.2019.5443
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: